09:40 AM EST, 01/02/2025 (MT Newswires) -- NervGen Pharma ( NGENF ) on Thursday said it has enrolled the 20th and final subject in the chronic cohort of its Phase 1b/2a trial evaluating its lead candidate, NVG-291, in individuals with spinal cord injury (SCI). The chronic cohort involves patients who suffered SCI up to 10 years prior.

The company has also been given the official go-ahead to amend its Phase 1b/2a clinical trial. NervGen has begun screening subjects for the subacute cohort (20 - 90 days post injury) of the study.

"We are pleased to share that enrollment is complete in the chronic cohort of our Phase 1b/2a clinical trial in traumatic spinal cord injury," said Daniel Mikol, NervGen's Chief Medical Officer. "Following the conclusion of the 16-week trial for the last enrolled patient, we can proceed with the next step, which is to ensure all data are thoroughly collected, and reviewed, including database lock, unblinding, and in-depth analysis of the results."

The company expects to announce topline results in the second quarter of this year.

NervGen's NVG-291 targets nervous system repair and has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration.

Price: 3.31, Change: +0.17, Percent Change: +5.41